A company insider just bought 2,916,666 shares of this penny stock!

This penny stock in my ISA has lost over half its value this year. But with directors buying shares recently, I’m wondering if I should do the same.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Creo Medical (LSE: CREO) has been a disappointing penny stock recently. It’s slumped 57% in 2024 and now trades for 19p. For context, it was going for 215p back in 2021.

One key issue for the medical device company lately has been a need to shore up its balance sheet to fund its growth opportunities. It recently raised £12m through a share placement priced at 24p.

I started buying this stock at around 42p a while back, then doubled down at a price of 28p in the summer. So I’m well down by now.

Should you invest £1,000 in JD Sports right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if JD Sports made the list?

See the 6 stocks

However, I note insiders have been taking up the offer of new shares. I didn’t join them. But should I buy more at 19p? Here are my thoughts.

Created with Highcharts 11.4.3Creo Medical Group Plc PriceZoom1M3M6MYTD1Y5Y10YALL27 Oct 201927 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

Skin in the game

On 21 October, Creo’s non-executive chairman Kevin Crofton acquired 2,916,666 shares at a price of 24p each. This transaction totalled approximately £700k.

At the same time, chief financial officer Richard Rees snapped up nearly £50k worth of shares.

It’s always good to see insiders purchasing shares. As Wall Street legend Peter Lynch once pointed out: “Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.”

Of course, that doesn’t mean the share price will rise. It’s on a worrying downwards trajectory.

What is Creo anyway?

For those unfamiliar, the firm develops minimally invasive electrosurgical devices. Its flagship Speedboat product, powered by proprietary energy technology, combines radiofrequency cutting with microwave coagulation.

Put simply, this helps surgeons remove cancer and pre-cancer more effectively from the lower gastro-intestinal tract before it spreads. The firm’s MicroBlate tool is focused on treatments for various cancers.

According to data collected from over 130 patients, Creo’s technology saved East Kent Hospitals University NHS Trust over £5,000 per procedure undertaken. And it provided a 91% reduction in accommodation costs per patient.

So there is great growth potential for the company as hospitals around the world (hopefully) adopt these cutting-edge devices. But it won’t happen overnight as doctors need to be trained to use them.

Growing pains

The firm recently released a disappointing set of interim results. Revenue of £15.2m was down from £15.7m the year before, meaning zero growth. And the underlying EBITDA loss increased to £10.5m, from a loss of £9.2m in H1 2023.

Creo initially projected reaching EBITDA breakeven by 2026, but that target has now been pushed back to 2028. So the company is to remain loss-making for longer than originally planned, which is a key risk here.

On the positive side, the company should be well-capitalised after selling a 51% stake in its European business. Combined with the share placement, this will give the firm around £40m.

Management says this will make Creo “sufficiently well-funded to reach profitability“.

Will I buy more shares?

The company has exciting growth potential. Its MicroBlate technology is currently in trials with Intuitive Surgical‘s Ion robot for lung cancer treatment. This combination would enable clinicians to diagnose and treat tumours in the same procedure.

However, I found the sudden lack of revenue growth in H1 a bit worrying. Consumable sales fell by 6%. Until I’m more confident in the growth trajectory again, I’m not adding to my holding, even at 19p.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Creo Medical and Intuitive Surgical. The Motley Fool UK has recommended Intuitive Surgical. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Last week, Rolls-Royce shares were the most popular on this investor platform. But there’s a catch!

Those using the Hargreaves Lansdown website bought more Rolls-Royce shares than any other UK stock last week. But this isn’t…

Read more »

Investing Articles

Here’s how to start investing with £500 as the stock market tumbles

Christopher Ruane reckons a rocky stock market could throw up some bargains, potentially making it a good moment to start…

Read more »

Investing Articles

Down 44% this year, could the Aston Martin share price bounce back?

The Aston Martin share price is in pennies and barely a 10th of what it was five years ago. Could…

Read more »

Young female analyst working at her desk in the office
Dividend Shares

A 9.28% dividend yield? Here’s the forecast for HSBC in 2025 and beyond

Mark Hartley considers the long-term prospects of the UK's largest bank, examining the reasons behind its surging dividend yield and…

Read more »

Investing Articles

A rally could be coming for the UK stock market! Here’s how I aim to profit

Mark Hartley considers a strategy to profit from a potential UK market rally. Which stocks are best-positioned to sidestep the…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Is the rare dip in this FTSE powerhouse’s share price just the right time for investors to consider buying it?

This FTSE 100 banking giant has seen its price tumble following the US tariffs news, but could the rare dip…

Read more »

Investing Articles

After an 18% fall, is Rolls-Royce’s share price now just too cheap for me to ignore?

Rolls-Royce’s share price was caught in the recent FTSE 100 sell-off. But now might be the time for me to…

Read more »

Investing Articles

11% yield! Could this UK stock  be a huge opportunity for investors targeting a second income?

An double-digit dividend yield could be second-income buying opportunity if the stock market is underestimating this UK translation company. 

Read more »